Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLRK1 | P26718 | 8/20 | 0.38 |
| ▸ | MICA | Q29983 | 8/20 | 0.38 |
| ▸ | RAET1L | Q5VY80 | 8/20 | 0.38 |
| ▸ | NAMPT | P43490 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762423 | 1.00 | KLRK1 (0.38) | KLRK1MICARAET1LNAMPTCYP3A4 | |
| SCHEMBL264420 | 0.86 | CYP3A4 (0.44) | CYP3A4 | |
| SCHEMBL264421 | 0.86 | CYP3A4 (0.44) | CYP3A4 | |
| SCHEMBL4157076 | 0.83 | CCR2 (0.39) | CYP3A4PPARGPPARA | |
| SCHEMBL4157072 | 0.83 | CCR2 (0.39) | CYP3A4PPARGPPARA | |
| SCHEMBL8081500 | 0.83 | RECQL (0.38) | NAMPTCYP3A4CYP3A5HIF1AEPAS1 | |
| SCHEMBL3650354 | 0.83 | PPARA (0.38) | PPARGPPARA | |
| SCHEMBL266804 | 0.82 | CTSS (0.38) | KLRK1MICARAET1LPPARGPPARA | |
| SCHEMBL266805 | 0.82 | CTSS (0.38) | KLRK1MICARAET1LPPARGPPARA | |
| Hydrochloric Acid SCHEMBL3641157 | 0.82 | RECQL (0.37) | NAMPTCYP3A4CYP3A5HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036422-A1 | MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, MTNR1A | KLRK1 4385/4885MICA 3690/4885RAET1L 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.